Showing posts with label Clarient. Show all posts
Showing posts with label Clarient. Show all posts

Wednesday, December 7, 2016

A Tough Macro Environment Is Masking Some Improvement At PolyOne

It has been a while since I've written on PolyOne (NYSE:POL), and I wasn't all that fond of the valuation on this specialty chemical company back in that last article in 2013. Since then, the share's performance has been about half that of the S&P 500, though somewhat less disappointing relative to other chemical companies like Schulman (NASDAQ:SHLM), Clariant (OTCPK:CLZNY), and Westlake (NYSE:WLK).

Performance has been hurt not only by execution issues in the acquired Spartech business, but also a weakening macro environment, and this most recent quarter was the first in over two years to show year-on-year revenue down (though organic growth was still negative absent an adjustment for energy-based pricing).

The investment prospects for PolyOne are more interesting to me now. I like specialty chemical companies, and I think PolyOne has a lot going for it with an array of value-adding capabilities. I also like that management has been shoring up some weaknesses and continuing to push the company in the direction of "value over volume" and toward a model that could conceivably produce double-digit ROICs on a more consistent basis.

Valuation isn't a slam-dunk, but I've learned that it is worth paying attention when quality specialty chemical companies look reasonably priced on a discounted cash flow basis, as the market is often willing to pay premiums to that value in healthier economic times.

Click here for more:
A Tough Macro Environment Is Masking Some Improvement At PolyOne

Friday, October 22, 2010

GE Goes Outside The Box In Healthcare

There is an old saying that if you are going to make predictions, you may as well make a lot of them. Even though I recently laid out multiple medical technology acquisition prospects for General Electric (NYSE:GE), GE managed to go off the board with an interesting purchase. 

On Friday morning, GE announced an agreement to acquire Clarient (Nasdaq:CLRT), a specialist in oncology diagnostics services. GE is paying cash in this deal, giving common shareholders $5 a share (versus Thursday's close of $3.74) and preferred shareholders $20 per share. That is a total deal value of $580 million for a company with about $100 million in trailing revenue.

As a major holder (more than 30 million shares as of September), Safeguard Scientifics (NYSE:SFE) will benefit significantly from this deal, booking roughly a $145 million gain in the transaction. (For more, see Is GE About To Stir Up The Medical Arena?)


Please click the link for the full article:
http://stocks.investopedia.com/stock-analysis/2010/General-Electric-Goes-Outside-The-Box-In-Healthcare-GE-CLRT-LH-DGX-SFE-GXDX1022.aspx